The HEXB Knockout A-549 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population originating from the A-549 human lung adenocarcinoma epithelial cell line. Targeted disruption of the HEXB gene via CRISPR/Cas9 creates a heterogeneous pool of A-549 cells with abolished HEXB expression, providing a robust loss-of-function model. The cells exhibit loss of HEXB protein as confirmed by immunoblotting, and the polyclonal nature ensures population-level coverage of gene disruption. The product is supplied as a frozen vial of viable cells for immediate culture and expansion.
The parental A-549 cell line was originally established from a 58-year-old male with lung adenocarcinoma and serves as a model of human alveolar basal epithelial cells. A-549 cells exhibit epithelial characteristics and are permissive to studies of lysosomal function, autophagy, and metabolic reprogramming. These cells are adherent, easily transfectable, and have been extensively characterized for nucleic acid and protein expression profiles. Their cancer origin provides a relevant background for investigating the intersection of lysosomal storage pathology with oncogenic signaling.
HEXB encodes the ??-subunit of hexosaminidase A (HexA, ???? heterodimer) and B (HexB, ?¦? homodimer), enzymes that hydrolyze terminal N-acetyl-D-hexosamine residues from GM2 gangliosides. HexA activity requires the GM2 activator protein (GM2A). Knockout of HEXB eliminates both enzymes, preventing GM2 degradation to ceramide and sphingosine, leading to GM2 accumulation. This results in impaired GM2 ganglioside turnover and altered sphingolipid signaling. HEXB transcription is regulated by MiT/TFE factors TFEB, MITF, and TFE3 downstream of mTORC1 and nutrient status. HEXB interacts with HEXA, LAMP1/2, and cathepsins for lysosomal function. Loss of HEXB disrupts glycosphingolipid metabolism, ceramide production, and lysosomal homeostasis.
In A-549 cells, HEXB knockout establishes an epithelial model of GM2 gangliosidosis, distinct from traditional neuronal models. The accumulation of GM2 gangliosides provides a quantifiable metabolic defect, while the cancerous origin allows interrogation of how lysosomal stress contributes to tumor biology, including proliferation, apoptosis resistance, and metastasis. The A-549 background??s robust autophagic flux enables precise monitoring of autophagy-lysosome pathway changes. This model is thus valuable for testing enzyme replacement, chaperone therapies, and autophagy modulators.
Researchers can employ immunoblotting for HEXB, RT-qPCR, and hexosaminidase enzyme activity assays for validation. Subsequent phenotypic analysis may include immunofluorescence staining for LAMP1 to assess lysosomal expansion, mass spectrometry-based GM2 ganglioside quantification, and untargeted cellular lipidomics. Lysosomal pH measurements with ratiometric dyes and LC3-II turnover assays provide functional autophagy readouts. The pool is suitable for drug screens targeting Sandhoff disease, sphingolipid metabolism, or mTORC1 signaling. For further details, please contact Ascent Research.
